As described in chapter macular degeneration, a positive effect the tocotrienols in macular degeneration would be expected. In the following individual case, the following beautiful individual case report was reported to me.
History: A woman, 64, who is not taking medication, receives the diagnosis from an eye doctor: macular degeneration. While only one eye is initially affected by vision loss, about a year ago the vision in the second eye also deteriorated. The doctor promised no treatment. Since the side effects were feared and there was a chance of success, she decided to use tocotrienolsn.
1) d-T3 has an anti-angiogenic effect "We showed delta-T3 (2.5-5 microM) completely abolished proliferation, migration and tube formation of human umbilical va endothelial cells (HUVECs)" . [PMID 19702331] several anthee
2) Anti-angiogenesis can be disrupted by alpha-tocopherol (conventional vitamin E) [PMID 25662730]
3) tocotrienols, also reach the eye in local application (topical) [PMID 15506242] [PMID 15506242].
4) Age-related macular degeneration appears to be strongly linked to inflammatory processes [PMID 26292978]. The anti-inflammatory tocotrienols, which have no side effects, are ideal.
5) According to the study in (1) and according to a precursor study (published Asia Pac J Clin Nutr 2008;17(S1):253-256), the anti-angiogenesis effect occurs reliably in T3 concentrations of 10 μmol. However, at low concentrations, the studies showed an increase in HUVEC formation.
The current findings seem to justify new studies with the use of tocotrienolsn against macular degeneration. This could lead to T3-based drug. Since tocotrienols cannot be patented as a natural product and pharmaceutical companies can therefore have an incentive to develop drugs, further research would probably have to be carried out through public research.
As a specialist in tocotrienols, I would like to suggest the following boundary conditions for new studies:
- The dosage should be chosen rather high, since the "(2.5-5 microM)" mentioned in (1) is at the upper limit of the oral achievable level. For humans, a high dosage would be, for example, 600 mg T3/d. Because of the short half-life in plasma, the total amount should be divided into 2 to 4 parts throughout the day.
- From (2) it follows that care must be taken to ensure that a) additional alpha-tocopherol is taken, and b) tocotrienol sources with a low content of tocopherols should be used. Delta-tocotrienol (i.e. Annatto) should be used preferably - because it is successful in (1).
- From (3) and (1) it follows that the oral administration of T3 should be supplemented by a topical application around the eye. Tocotrienols move relatively quickly by a few centimeters under the skin, which, as the studies in (3) make possible, they do notinApply your eye to the surrounding skin.
- From (5) it follows that low tissue concentrations could even have a counteractive effect. All applications must therefore be carried out at least in high dosages and with consistent use.
(4) recommends tocotrienols for use on the eye.
One study from 2012 also suggests the additional use of resveratrol and “zinc, antioxidants, carotenoids, n-3 essential fats” and vitamin D. Resveratrol is particularly recommended because, as an NF-kB inhibitor, it could potentially have a synergistic effect with tocotrienol.
Summary: The intake of tocotrienolsn as well as the topical application around the eye could contribute to the treatment of macular degeneration through the anti-angiogenic and the anti-inflammatory effect and without side effects.
